Nanotechnology Now - Press Release: GenScript launches a premier gene synthesis service “Gene-BrickTM” for building large DNA fragments

Home > Press > GenScript launches a premier gene synthesis service “Gene-BrickTM” for building large DNA fragments

Abstract:
GenScript USA Inc., an internationally recognized biology contract research organization (CRO) recently launched Gene-BrickTM, a premier gene synthesis service.

The Gene-BrickTM premier gene synthesis service is specifically designed to meet demands of large DNA fragments which are used in synthetic biology research, such as the building of large genetic circuits and synthetic chromosomes.

GenScript launches a premier gene synthesis service “Gene-BrickTM” for building large DNA fragments

Piscataway, NJ | Posted on June 12th, 2012

Gene-BrickTM services will synthesize ~10 Kb long DNA fragments as the fundamental building block of a synthetic genome. GenScript will deliver the 8-13 Kb full-length, synthetic DNA fragments with 100% guaranteed sequence accuracy. Being the first and the only commercial service provider of Gene-Brick synthesis, GenScript will make genome synthesis easier, faster, and less risk.

####

About GenScript
GenScript USA, Inc., is a leading biology CRO focusing on early drug discovery and development services. Built on assembly-line mode, one-stop solution, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into value chain and operations. GenScript is the largest gene synthesis provider in the U.S. Their customers include top pharmaceutical companies, major biotech firms and research institutions in over 70 countries.

For more information, please click here

Contacts:
Kathy
kathy.li@genscirpt.com

Sally Wang
Executive Vice President
GENSCRIPT USA Inc.
1-(732) 885-9188

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: